Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065454 | 0.91 | ALDH1A1 (0.36) | PPARGSPRCYP2C9OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL5061752 | 0.90 | ALDH1A1 (0.35) | PPARGSPRCYP2C9OPRD1OPRK1 | |
| SCHEMBL5057786 | 0.77 | CNR1 (0.48) | CNR1PPARGTP53GAA | |
| SCHEMBL9109184 | 0.69 | SPR (0.44) | SPRCCR3 | |
| SCHEMBL2578514 | 0.67 | CCR5 (0.41) | PPARGCYP2C9OPRD1OPRK1 | |
| SCHEMBL17766766 | 0.66 | FAAH (0.39) | — | |
| SCHEMBL4789205 | 0.66 | KMT2A (0.42) | CCR3 | |
| SCHEMBL2586402 | 0.66 | KMT2A (0.42) | CCR3 | |
| SCHEMBL5062062 | 0.66 | ALDH1A1 (0.48) | PPARGTP53CYP2C9 | |
| SCHEMBL778489 | 0.66 | ALDH1A1 (0.39) | SPRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | claimed |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | ARENA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | ARENA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | ARENA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1735622-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005116653-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | GPR119, GCGR, GLP1R | CNR1 90/4885PPARG 101/4885SPR 1413/4885 |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | GPR119, GCGR, GLP1R | CNR1 90/4885PPARG 101/4885SPR 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.